Non Hodgkin Lymphoma News and Research

RSS

Study finds higher risk of all-cause mortality among pediatric cancer patients in LMICs during the pandemic

During the first nine months of the COVID-19 pandemic, pediatric cancer patients from lower- and middle-income countries faced a higher risk of all-cause mortality than those in high-income countries, according to data presented at the AACR Annual Meeting 2022, held April 8-13.

11 Apr 2022

Most cancer patients develop antibodies after receiving COVID-19 vaccine, study shows

Cancer patients who have compromised immune systems due to their disease or therapy remain at high risk for COVID-19 infection.

10 Mar 2022

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

2 Feb 2022

Study provides a new treatment option for patients with relapsed B-cell lymphoma

A new therapy showed improvement over the standard treatment for relapsed B-cell lymphoma, according to a study published in the New England Journal of Medicine.

26 Jan 2022

New grant program launches to advance therapeutic discovery for follicular lymphoma

Today saw the launch of a dedicated grant program aimed at advancing therapeutic discovery for follicular lymphoma (FL), The Follicular Lymphoma Foundation (FLF) CURE FL Awards - Curative Research to Eliminate Follicular Lymphoma.

10 Jan 2022

Lymphoma patients can benefit from early CAR T treatment, study shows

Chimeric antigen receptor T-cell therapy or CAR T is a breakthrough treatment for patients with certain types of blood cancers.

13 Dec 2021

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

12 Dec 2021

Mutations in a crucial gene responsible for chemotherapy failure in some blood cancer patients

Mutations in a crucial gene are the key reason that chemotherapy fails in some patients with blood cancer, a study by Nanyang Technological University, Singapore (NTU Singapore) and Singapore General Hospital (SGH) has found.

6 Dec 2021

Study quantifies the life-years lost to cancer among transplant recipients

People who have received organ transplants face an elevated risk of developing cancer, primarily due to immunosuppression from medications to prevent organ rejection, as well as underlying medical conditions.

20 Sep 2021

Distinct changes found in cancer and non-cancer immune cells in Waldenstrom macroglobulinemia

A new study by researchers at Winship Cancer Institute of Emory University finds that cancer-associated mutations originate in blood progenitor cells, leading to distinct changes in both cancer and non-cancer immune cells in Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma and its precursor IgM monoclonal gammopathy of undetermined significance (MGUS).

2 Sep 2021

Modified R-CODOX-M/IVAC regimen shows promise for treating sporadic Burkitt lymphoma

Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin lymphoma (NHL) that comes in three different variants: endemic, immunodeficiency-associated, and sporadic. Of these variants, sporadic BL is most commonly found outside malaria-endemic countries and typically seen in young adults.

1 Sep 2021

Study may help refocus research efforts on adolescent and young adult cancer survivorship

Survival rates for adolescents and young adults diagnosed with cancer have varied considerably depending on cancer type.

26 Jul 2021

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma.

23 Jul 2021

RESILIENCE project aims to reduce the burden of cardiovascular disease in cancer survivors

Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects.

30 Jun 2021

New research uncovers substantial differences in rates of childhood cancers

New research uncovers substantial differences in rates of childhood cancers when considering single year of age rather than grouping several years together.

21 Jun 2021

Cognitive outcomes in survivors of childhood cancers have been largely understudied

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income.

23 Apr 2021

Race, neighborhood poverty, insurance associated with higher mortality in people under 40 with cancer

Being Black or Hispanic, living in high-poverty neighborhoods, and having Medicaid or no insurance coverage are associated with higher mortality in men and women under 40 with cancer, a review by UT Southwestern Medical Center researchers found.

22 Apr 2021

Researchers identify long-sought enzyme that prevents cancer

Researchers have found a long-sought enzyme that prevents cancer by enabling the breakdown of proteins that drive cell growth, and that causes cancer when disabled.

14 Apr 2021

SwRI researchers part of two collaborative teams receive SAMF bioscience grants

Collaborative teams that include Southwest Research Institute staff received two of six recently awarded San Antonio Medical Foundation (SAMF) bioscience grants. SwRI, in collaboration with UT Health San Antonio and University Health System, received a nearly $200,000 grant to develop machine learning algorithms for cancer detection.

31 Mar 2021

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

An innovative cell-based treatment for cancer has been found promising for the control of infections caused by fungi.

4 Mar 2021